{
  "drug_id": "D008",
  "drug_name": "Hepatrel",
  "indication": "Liver-E",
  "modality": "siRNA therapy",
  "mechanism": "gene expression silencer",
  "moa_short": "Reduces target mRNA to decrease protein expression.",
  "formulation": "prefilled syringe",
  "route": "subcutaneous",
  "regimen": "100 mg Q4W",
  "trial_id": "AMGN-D008-401",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Hepatrel 100 mg Q4W",
      "n": 237,
      "dose": "100 mg Q4W"
    },
    {
      "name": "Placebo",
      "n": 208,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Liver-E with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Mean change in Composite Index at Week 24",
    "endpoint_secondary": "Durable response at Week 24",
    "primary_effect": "LS mean difference -1.11 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.01630907060444526,
    "primary_ci": "[-1.51, -0.71]",
    "secondary_effect": "Numerically favored active arm; supportive trend",
    "discontinuation_rate_pct": 4.55112040992104
  },
  "safety": {
    "common_ae": [
      [
        "Arthralgia",
        9.526454050028057
      ],
      [
        "Rash",
        7.594591037320784
      ],
      [
        "Elevated ALT",
        6.078927125924658
      ],
      [
        "Diarrhea",
        4.945344368180757
      ],
      [
        "Upper respiratory infection",
        2.975157264620878
      ],
      [
        "Injection-site reaction",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 3.399784469106269,
    "discontinuation_ae_rate_pct": 3.3901815901604238,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v1.8",
  "doc_date": "2025-12-26"
}